CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dechra Pharmaceuticals plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dechra Pharmaceuticals plc
24 Cheshire Avenue
Cheshire Business Park, Lostock Gralam
Phone: +44 1606814730p:+44 1606814730 NORTHWICH, CW9 7UA  United Kingdom Ticker: DPHDPH
This company was Merged or Acquired on 1/16/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company’s segments include European Pharmaceuticals, NA Pharmaceuticals, and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment comprises of Dechra Veterinary Products EU, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing & Supply. This Segment operates internationally and manufactures and markets Companion Animal Products (CAP), Equine, Food producing Animal Products (FAP) and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Dechra Veterinary Products Canada, and Dechra Productos Veterinarios (Mexico), which sell CAP, Equine and FAP in those territories. The Segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas. The Pharmaceuticals Research and Development Segment includes all of the Company's pharmaceutical research and development activities.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20236/30/2023Yes---Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board AlisonPlatt 1/1/2022 3/1/2020
Chief Executive Officer, Executive Director Ian D.Page 11/1/2001 6/13/1997
Chief Financial Officer, Executive Director PaulSandland 10/30/2019 1/1/2010
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Apex Laboratories N.Z. Limited
Apex Laboratories Pty Ltd.
Arnolds Veterinary Products Limited
50 additional Business Names available in full report.

General Information
Number of Employees: 2,335 (As of 6/30/2023)
Outstanding Shares: 113,905,890 (As of 12/18/2023)
Shareholders: 1,427
Stock Exchange: LON
Fax Number: +44 1606814731


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024